← BackBIO-TECHNE Corp · BiotechTECH
Low riskNext report: Around Nov 4 (est.)
The short versionA profitable company with steady sales.
Going well
- Profitable every year for 10 years
- Brings in more cash than it spends
- Little debt
Money moves
- No insider buying or selling in the last 30 days
- Institutions cut 1.2% from their holdings in the quarter ending June 2026 (284 bought, 353 sold)
- Held by George Soros (Soros Fund), Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$72.69+0.2% that day
- Company value
- $11.4B
- Share price times all shares
- Price vs profit (P/E)
- 63.2x
- You pay about $63 for each $1 of yearly profit
- Price vs sales
- 9.4x
- Company value is 9.4 times a year of sales
- Dividend yield
- 0.4%
- Yearly dividend as a share of today's price
- Cash vs value
- 2%
- Cash as a share of company value
- Debt vs value
- 2%
- Debt as a share of company value
From TECH's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26 (worked out from yearly totals)$321.2M+1.3% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.2B, down 0.4% from the 12 months before. Over 5 years, sales grew about 11% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.3.6%
- PassDebt under half of equityNot relying on borrowed money.0.13x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.6.0%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$256.6M
- PassShare count not growingNot diluting owners. Falling means buybacks.-2.7% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.64.8%
- Revenue
- $1.2B
- +5.2% vs prior year
- 5-year growth
- +10.5%/yr
- revenue, per year
- Total debt
- $260.0M
- 0.13x equity
- Current ratio
- 4.54x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $321.2M
- +1.3% YoY
- EPS
- $0.35
- vs -$0.11
- Op. margin
- 23.1%
- +30.6 pts
- Gross margin
- 65.8%
- +3.1 pts
- Free cash flow
- $86.9M
- Share count
- +0.8%
- vs a year ago
Some values are worked out from year-to-date totals in the annual report.
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 2.2
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady-1.2%Institutions cut 1.2% from their holdings. 284 bought, 353 sold.
Shares held by institutions175.3M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-0.3%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.1x · $200.0M debtShares outstandingLatest reported
157MNext reportAround Nov 4 (est.)Estimated from the same quarter last year
- Results filedAug 12
- Results filedMay 6
- Results filedFeb 4
- Results filedNov 5, 2025
- Results filedAug 6, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Option exerciseJohn L HigginsDirector
15,940 shares
- +24% of holdings
- Now owns 82,816 shares
- Exercise price $25.30
- Filed 2 days after trade
- Also: Shares withheld for taxes
Option exerciseRobert V BaumgartnerDirector
15,940 shares
- +34% of holdings
- Now owns 62,443 shares
- Exercise price $25.30
- Filed 2 days after trade
- Also: Shares withheld for taxes
Stock awardSteven C. CrousePresident - Diag & Spatial Bi
22,842 shares
- Now owns 14,140 shares
- Restricted Stock Units
- 2 transactions
- Filed 2 days after trade
Stock awardWilliam GeistPRESIDENT, PROTEIN SCIENCES
38,747 shares
- Now owns 23,985 shares
- Restricted Stock Units
- 2 transactions
- Filed 2 days after trade
Stock awardAmy E. HerrDirector
1,381 shares
- Now owns 1,381 shares
- Restricted Stock Units
- Held by significant other
- Filed 2 days after trade
Stock awardJames HippelCFO
58,897 shares
- Now owns 36,459 shares
- Restricted Stock Units
- 2 transactions
- Filed 2 days after trade